Archives: Speakers

Chris has over 27 years experience in product and service development within regulated industries across multiple markets. The last 13+ years have focused on Clinical technologies; including tools and platforms to, engage, educate and retain participants (and their families) in clinical studies. Chris is a recognised subject matter expert in eCOA and patient engagement, with a proven ability in the technical domain. Chris believes in the utilisation of technology for the benefit of all and is a proponent of change, so that our industry is able to support the globalisation of clinical research, which supports diverse participant populations.

Experienced clinical operations professional with proven successful delivery of complex local and global studies as well as accountability for an extensive portfolio of studies (phase I-IV) in the Pharmaceutical industry. Experience in heading up large departments (over 100 staff).
Is recognised for being an insightful, reliable, trusted and resilient leader. Has held a number of roles with increasing seniority within three different pharma companies.
Extensive vendor selection and top ten CRO oversight experience. Trusted team leader on cross functional matrix teams and multiple governance committees.
Sound financial acumen, with accountability for budgets at study and portfolio level.
Thirteen yrs experience in coaching and line management (including second line management).
Recent therapeutic area focus has been in Rare Diseases, particularly gMG. Previous experience in the areas of cardiology, diabetes, RA and Neuroscience as well as infectious diseases, ophthalmology and breast cancer.

James is a Corporate Responsibility and Sustainability Executive at City accountants, Buzzacott. James’ responsibilities cover the spectrum of ESG and corporate responsibility within Buzzacott which involves working alongside teams across the firm to support the firm’s philanthropic objectives, diversity, and inclusion, as well as environmental sustainability.

Having previously worked in volunteer management and fundraising/grant-making roles in the charity sector, James undertook an MSc in Corporate Responsibility & Sustainability at the University of London (Birkbeck).

Majid joined Janux in June 2022 as executive director and head of clinical biomarkers responsible to devise strategy, source best technology and platforms and execute comprehensive laboratory testing plans in support of Janux clinical studies.  Majid has over 15 years of experience in some of the most challenging areas of oncology therapeutics with a primary focus on predictive oncology clinical development. Trained as a translational pathologist he has held impactful positions with increasing responsibilities at large pharmaceutical and small to medium biotech companies including Novartis, Celgene, Juno Therapeutics, Five Prime, and Poseida Therapeutics.

Majid has a Doctor of Veterinary Medicine degree, a postgraduate diploma and a PhD from the University of Queensland in Australia.